Siemens Healthineers Opens Innovation Center in Erlangen

Siemens HealthineersSiemens Healthineers has opened its new Innovation Center in Erlangen, Germany, in the heart of the regional medical technology research area known as Medical Valley. The focus is on open innovation by collaborating with external partner companies, start-ups and academic and clinical institutions to improve healthcare worldwide. The innovation center complements an existing ecosystem of centers in Shanghai, China, and Bengaluru, India. The underpinning idea is to create an infrastructure to strengthen innovation across the region, promote open collaboration in research, development and production, and enable customer- and market-oriented development.

"With our new Innovation Center, we are highlighting our commitment to the Erlangen and Forchheim locations and continuing to consistently implement our strategy of an open innovation culture," said Peter Schardt, Chief Technology Officer (CTO) of Siemens Healthineers. "The goal is to jointly focus on new technologies and value-added processes that have the potential to disrupt the healthcare system for the benefit of patients. By promoting open collaborations and projects, Siemens Healthineers and its customers will enable more people around the world to access high-quality medical care - from precise diagnosis to the right therapy."

Among other things, the company’s ASOR community has a co-working space in the new premises to further advance research and development for extended reality applications with internal and external partner companies, and to make digital content more tangible. Specifically, the aim is to test and develop prototypes and to virtually simulate medical technology solutions and applications, for example for training.

The Innovation Center is also home to partnerships such as the digital health innovation platform d.hip, an alliance of industry, university medicine and research organizations which aims to advance the digitization of the healthcare system.

In fiscal 2022 Siemens Healthineers invested around €1.8 billion in research and development and holds around 23,000 technical property rights, including around 15,000 granted patents.

About Siemens Healthineers

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers and its regional companies are continuously developing their product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company's foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers' ability to provide high-quality, efficient care. In fiscal 2022, which ended on September 30, 2022, Siemens Healthineers, which has approximately 69,500 employees worldwide, generated revenue of around €21.7 billion and adjusted EBIT of almost €3.7 billion.

Most Popular Now

Study Finds One-Year Change on CT Scans …

Researchers at National Jewish Health have shown that subtle increases in lung scarring, detected by an artificial intelligence-based tool on CT scans taken one year apart, are associated with disease...

Yousif's Story with Sectra and The …

Embarking on healthcare technology career after leaving his home as a refugee during his teenage years, Yousif is passionate about making a difference. He reflects on an apprenticeship in which...

New AI Tools Help Scientists Track How D…

Artificial intelligence (AI) can solve problems at remarkable speed, but it’s the people developing the algorithms who are truly driving discovery. At The University of Texas at Arlington, data scientists...

AI Tool Offers Deep Insight into the Imm…

Researchers explore the human immune system by looking at the active components, namely the various genes and cells involved. But there is a broad range of these, and observations necessarily...

New Antibiotic Targets IBD - and AI Pred…

Researchers at McMaster University and the Massachusetts Institute of Technology (MIT) have made two scientific breakthroughs at once: they not only discovered a brand-new antibiotic that targets inflammatory bowel diseases...

Highland to Help Companies Seize 'N…

Health tech growth partner Highland has today revealed its new identity - reflecting a sharper focus as it helps health tech companies to find market opportunities, convince target audiences, and...